Platform Discovery & Target Validation
Oncology
Pre-clinicalActive
Key Facts
About TenSixty BioSciences
TenSixty BioSciences is a private, pre-clinical stage biotech leveraging an integrated platform of cell models, high-throughput screening, and AI/ML to map the surfaceome of cancer cells and discover novel antibody targets. The company's mission is to identify precise targets and develop transformative biologics for oncology, moving beyond traditional discovery paradigms. Backed by undisclosed world-class investors, TenSixty operates from San Diego, CA, with a listed address in Cambridge, MA, and is building an interdisciplinary team to drive its ambitious goals. The company is currently pre-revenue and focused on platform validation and early pipeline development.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |